CELESTONE SOLUSPAN (betamethasone acetate)
CELESTONE SOLUSPAN is indicated for the treatment of Asthma; Atopic Dermatitis; Contact Dermatitis; Drug Hypersensitivity; Allergic Rhinitis; Serum Sickness; Transfusion Reaction; Dermatitis Herpetiformis; Exfoliative Erythroderma; Mycosis Fungoides.
How CELESTONE SOLUSPAN Works
Betamethasone is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive activity. It diffuses across cell membranes and binds with high affinity to specific cytoplasmic glucocorticoid receptors. This complex translocates to the nucleus, where it binds to glucocorticoid response elements (GREs) on DNA, altering gene expression. This results in the induction of anti-inflammatory proteins (such as lipocortins, which inhibit phospholipase A2) and the inhibition of the synthesis of pro-inflammatory mediators (including prostaglandins, leukotrienes, and various cytokines). The SOLUSPAN formulation provides a dual-effect profile: the highly soluble betamethasone sodium phosphate provides rapid activity, while the slightly soluble betamethasone acetate provides sustained activity through slower absorption.
Details
- Status
- Prescription
- First Approved
- 1965-03-03
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
Companies
CELESTONE SOLUSPAN Approval History
What CELESTONE SOLUSPAN Treats
10 indicationsCELESTONE SOLUSPAN is approved for 10 conditions since its original approval in 1965. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Asthma
- Atopic Dermatitis
- Contact Dermatitis
- Drug Hypersensitivity
- Allergic Rhinitis
- Serum Sickness
- Transfusion Reaction
- Dermatitis Herpetiformis
CELESTONE SOLUSPAN Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in CELESTONE SOLUSPAN's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications CELESTONE SOLUSPAN treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to CELESTONE SOLUSPAN
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CELESTONE SOLUSPAN FDA Label Details
Indications & Usage
FDA Label (PDF)CELESTONE SOLUSPAN is indicated for the treatment of Asthma; Atopic Dermatitis; Contact Dermatitis; Drug Hypersensitivity; Allergic Rhinitis; Serum Sickness; Transfusion Reaction; Dermatitis Herpetiformis; Exfoliative Erythroderma; Mycosis Fungoides.
Explore on TheraRadar
Ulcerative Colitis Drug Landscape 2026
Approved therapies, pipeline drugs, and clinical trial intelligence
Related Intelligence
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.